David McClung - 30 Jun 2025 Form 4 Insider Report for BioCardia, Inc. (BCDA)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
02 Jul 2025, 21:03:36 UTC
Prior SEC filing
25 Apr 2025
Next SEC filing
10 Dec 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ David McClung

Key filing fact

David McClung filed Form 4 for BioCardia, Inc. (BCDA) on 02 Jul 2025.

Key facts

  • This page summarizes David McClung's Form 4 filing for BioCardia, Inc. (BCDA).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 02 Jul 2025, 21:03.

Change

  • Previous filing in this sequence was filed on 25 Apr 2025.
  • Current net transaction value: +$9,999.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001686155 Primary reporting owner

McClung David

Relationship
Chief Financial Officer
Address
C/O BIOCARDIA, INC., 320 SOQUEL WAY, SUNNYVALE
Signature
/s/ David McClung
Signature date
02 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCDA transaction

Common Stock

Purchase

Transaction value
$9,999
Shares
+4,819
Change %
+11%
Price
$2.08
Shares after
47,950
Date
30 Jun 2025
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCDA transaction Derivative

Warrant (right to buy)

Purchase

Transaction value
Shares
+4,819
Change %
+22%
Price
Shares after
26,275
Date
30 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,819
Exercise price
$1.95
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On June 30, 2025, the Registrant closed a private placement with certain qualified institutional buyers and institutional accredited investors, as well as the Reporting Person, wherein the Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .